Barclays
BPMC

Barclays’s Blueprint Medicines BPMC Stock Holding History

Barclays’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,556,918
Closed -$200M – 5498
2025
Q2 		$200M Buy
1,556,918
+1,427,323
+1,101% +$148M 0.05% 273
2025
Q1 		$11.5M Sell
129,595
-59,532
-31% -$5.81M ﹤0.01% 1310
2024
Q4 		$16.5M Buy
189,127
+17,931
+10% +$1.64M ﹤0.01% 1235
2024
Q3 		$15.8M Buy
171,196
+117,993
+222% +$11.7M ﹤0.01% 1192
2024
Q2 		$5.73M Sell
53,203
-12,192
-19% -$1.22M ﹤0.01% 1458
2024
Q1 		$6.2M Sell
65,395
-81,098
-55% -$6.96M ﹤0.01% 1707
2023
Q4 		$13.5M Buy
146,493
+19,948
+16% +$1.29M 0.01% 1301
2023
Q3 		$6.36M Buy
126,545
+22,198
+21% +$1.19M ﹤0.01% 1189
2023
Q2 		$6.59M Buy
104,347
+2,947
+3% +$160K ﹤0.01% 1190
2023
Q1 		$4.56M Sell
101,400
-22,786
-18% -$1.03M ﹤0.01% 1608
2022
Q4 		$5.44M Buy
124,186
+50,317
+68% +$2.41M ﹤0.01% 1563
2022
Q3 		$4.87M Buy
73,869
+48,428
+190% +$3.11M 0.01% 1180
2022
Q2 		$1.28M Sell
25,441
-2,427
-9% -$142K ﹤0.01% 2173
2022
Q1 		$1.78M Sell
27,868
-44,692
-62% -$3.21M ﹤0.01% 1956
2021
Q4 		$7.77M Buy
72,560
+28,481
+65% +$2.98M ﹤0.01% 1418
2021
Q3 		$4.53M Buy
44,079
+33,272
+308% +$3.1M ﹤0.01% 1703
2021
Q2 		$949K Sell
10,807
-44,861
-81% -$4.11M ﹤0.01% 2692
2021
Q1 		$5.41M Buy
55,668
+22,901
+70% +$2.29M ﹤0.01% 1453
2020
Q4 		$3.67M Sell
32,767
-7,540
-19% -$795K ﹤0.01% 1745
2020
Q3 		$3.74M Sell
40,307
-81,943
-67% -$6.31M ﹤0.01% 1604
2020
Q2 		$9.54M Buy
122,250
+64,912
+113% +$4.39M 0.01% 991
2020
Q1 		$3.35M Sell
57,338
-51,190
-47% -$3.29M ﹤0.01% 1819
2019
Q4 		$8.69M Buy
108,528
+80,468
+287% +$6.02M ﹤0.01% 1509
2019
Q3 		$2.06M Sell
28,060
-6,927
-20% -$599K ﹤0.01% 2828
2019
Q2 		$3.3M Buy
34,987
+7,208
+26% +$595K ﹤0.01% 2316
2019
Q1 		$2.22M Buy
27,779
+24,436
+731% +$1.81M ﹤0.01% 2458
2018
Q4 		$181K Sell
3,343
-27,471
-89% -$1.67M ﹤0.01% 4646
2018
Q3 		$2.4M Buy
30,814
+10,811
+54% +$751K ﹤0.01% 2664
2018
Q2 		$1.27M Buy
20,003
+7,946
+66% +$632K ﹤0.01% 3013
2018
Q1 		$1.1M Buy
12,057
+2,810
+30% +$242K ﹤0.01% 3086
2017
Q4 		$698K Buy
9,247
+6,331
+217% +$445K ﹤0.01% 3479
2017
Q3 		$203K Buy
2,916
+384
+15% +$20.5K ﹤0.01% 4411
2017
Q2 		$128K Sell
2,532
-12,923
-84% -$549K ﹤0.01% 4739
2017
Q1 		$618K Buy
15,455
+12,547
+431% +$449K ﹤0.01% 3198
2016
Q4 		$82K Buy
2,908
+2,665
+1,097% +$80.3K ﹤0.01% 4878
2016
Q3 		$7K Sell
243
-87
-26% -$2.16K ﹤0.01% 5904
2016
Q2 		$7K Buy
330
+200
+154% +$3.63K ﹤0.01% 5642
2016
Q1 		$2K Sell
130
-352
-73% -$6.11K ﹤0.01% 5851
2015
Q4 		$12K Sell
482
-191
-28% -$4.3K ﹤0.01% 5340
2015
Q3 		$14K Sell
673
-131
-16% -$3.62K ﹤0.01% 5618
2015
Q2 		$21K Buy
+804
New +$23K ﹤0.01% 5642

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's BPMC Position: Q3 2025 in Review

Barclays sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,556,918 shares — an estimated $200M sold.

Barclays first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $200M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Barclays reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 1,556,918 Blueprint Medicines shares in Q3 2025, an estimated $200M.
  • Barclays first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • Barclays's Blueprint Medicines position peaked at $200M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.